All In Biotech

Drug Trial Radar · NCT07768345

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Feb 2, 2028

Study completion Feb 2, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • RSVpreF VaccineBiological

    RSVpreF Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactionsTime frame: For up to 7 days after vaccination
  2. Percentage of participants reporting systemic eventsTime frame: For up to 7 days after vaccination
  3. Percentage of participants reporting adverse eventsTime frame: Through 1 month after vaccination
  4. Percentage of participants reporting newly diagnosed chronic medical conditionsTime frame: Through 12 months after vaccination
  5. Percentage of participants reporting serious adverse eventsTime frame: Through 12 months after vaccination
  6. Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination
  7. NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Foundation Hospital LAMC

    Los Angeles, California · Recruiting

  • Kaiser Permanente Los Angeles Medical center

    Los Angeles, California · Recruiting

  • Kaiser Permanente

    Los Angeles, California · Recruiting

  • University of Colorado Anschutz Medical Campus - Vaccine and Clinical Trials Clinic

    Aurora, Colorado · Recruiting

  • George Washington University

    Washington D.C., District of Columbia · Recruiting

  • The Hope Clinic of Emory University

    Decatur, Georgia · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Iowa, Infectious Disease Research Laboratory, VA Medical Center

    Iowa City, Iowa · Recruiting

  • Ochsner Clinic Foundation - Kenner Clinical Trials Unit

    Kenner, Louisiana · Recruiting

  • University of Maryland, Institute of Human Virology

    Baltimore, Maryland · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • University of Nebraska Medical Center/ Nebraska Medicine

    Omaha, Nebraska · Recruiting

  • NYU Langone Health Vaccine Center

    New York, New York · Recruiting

  • Rochester Clinical Research

    Rochester, New York · Recruiting

  • University of Rochester Investigational Drug Services

    Rochester, New York · Recruiting

  • University of Rochester Medical Center-Infectious Diseases Research Clinic

    Rochester, New York · Recruiting

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

  • Duke Clinics 2F, 2G

    Durham, North Carolina · Recruiting

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania · Recruiting

  • Epic Medical Research-Desoto

    DeSoto, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.